‡ Zinforo is contraindicated in patients with hypersensitivity to any active substance or excipient and should not be used in patients with a history of hypersensitivity to other cephalosporin-class antibiotics or who have had an immediate and severe hypersensitivity reaction (e.g., anaphylaxis to other ß-lactam antibacterial agents). Fatal hypersensitivity reactions are possible. Antibacterial-associated colitis and pseudomembranous colitis (Clostridium difficile) have been reported, including cases that were life-threatening. Patients with a pre-existing seizure disorder should use Zinforo with caution as seizures occurred in toxicology studies at doses higher than typical human exposures. DAGT (Coombs test) became positive in 11.2% of patients from five pooled pivotal studies in patients who received Zinforo every 12 hours and in 32.3% of patients who received Zinforo every 8 hours.¹
​​​​§Comparator therapies: cSSTI, ceftriaxone; CAP, vancomycin or cefazolin, plus optional aztreonam.
IIBased on two clinical trials in 227 paediatric patients aged from 2 months to 17 years. The most common adverse reactions occurring in ≥3% of patients treated with Zinforo were diarrhoea, rash and vomiting, and were generally mild or moderate in severity.^9,10
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.¹

^{​​​​​​​}​Abbreviations

CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; MRSA, methicillin-resistant Staphylococcus aureus.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References